- Home
- ELVN vs NCDL Comparison
ELVN vs NCDL Comparison
Compare ELVN & NCDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- NCDL
- Stock Information
- Founded
- ELVN 2016
- NCDL 2019
- Country
- ELVN United States
- NCDL United States
- Employees
- ELVN N/A
- NCDL N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- NCDL
- Sector
- ELVN Health Care
- NCDL
- Exchange
- ELVN Nasdaq
- NCDL NYSE
- Market Cap
- ELVN 1.1B
- NCDL 919.2M
- IPO Year
- ELVN 2020
- NCDL N/A
- Fundamental
- Price
- ELVN $21.86
- NCDL $17.15
- Analyst Decision
- ELVN Strong Buy
- NCDL Buy
- Analyst Count
- ELVN 5
- NCDL 6
- Target Price
- ELVN $37.80
- NCDL $18.33
- AVG Volume (30 Days)
- ELVN 220.2K
- NCDL 304.6K
- Earning Date
- ELVN 03-13-2025
- NCDL 02-22-2025
- Dividend Yield
- ELVN N/A
- NCDL 7.90%
- EPS Growth
- ELVN N/A
- NCDL N/A
- EPS
- ELVN N/A
- NCDL N/A
- Revenue
- ELVN N/A
- NCDL N/A
- Revenue This Year
- ELVN N/A
- NCDL N/A
- Revenue Next Year
- ELVN N/A
- NCDL N/A
- P/E Ratio
- ELVN N/A
- NCDL N/A
- Revenue Growth
- ELVN N/A
- NCDL N/A
- 52 Week Low
- ELVN $10.90
- NCDL $16.00
- 52 Week High
- ELVN $30.03
- NCDL $18.10
- Technical
- Relative Strength Index (RSI)
- ELVN 44.27
- NCDL 59.82
- Support Level
- ELVN $21.45
- NCDL $16.75
- Resistance Level
- ELVN $22.82
- NCDL $17.05
- Average True Range (ATR)
- ELVN 1.55
- NCDL 0.28
- MACD
- ELVN 0.00
- NCDL 0.08
- Stochastic Oscillator
- ELVN 32.63
- NCDL 95.45
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.